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a b s t r a c t
Pantethine (d-bis-(N-pantothenyl--aminoethyl)-disulfide, PAN), the stable disulfide form of panteth-
eine, has beneficial effects in vascular diseases being able to decrease the hyperlipidaemia, moderate
the platelet function and prevent the lipid peroxidation. Furthermore, recent studies suggested that PAN
maybe an effective therapeutic agent for cerebralmalaria and, possibly, for neurodegenerative processes.
Interestingly, in the literature, there were no data dealing with the chemical stability and the analytical
aspects of PAN. Hence, in the present work the chemical stability of PAN was for the first time established
througha forceddegradation study followedby liquid chromatography tandemmass spectrometry inves-
tigation showing the formation of three degradation products of PAN (PD1, PD2 and POx) arising from
hydrolytic, thermal and oxidative stresses. Based on these data a stability-indicating LC–UV method for
simultaneous estimation of PAN, and its most relevant degradation product (PD1) was developed and
validated; moreover the method allowed also the separation and the quantification of the preservative
system, constituted by a parabenmixture. Themethod showed linearity for PAN (0.4–1.2mgmL−1),MHB,
PHB (0.4–1.2gmL−1) and PD1 (2.5–100gmL−1); the precision, determined in terms of intra-day and
inter-day precision, expressed as RSDs, were in the ranges 0.4–1.2 and 0.7–1.4, respectively. The method
demonstrated to be accurate and robust; indeed the average recoveries were 100.2, 99.9, and 100.0%
for PAN, MHB and PHB, respectively, and 99.9 for PD1. By applying small variations of the mobile phase
composition, counter-ion concentration and pH the separation of analytes was not affected. Finally, the
applicability of this method was evaluated analyzing the available commercial forms at release as well
as during stability studies.
© 2014 Elsevier B.V. All rights reserved.
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1. IntroductionQ223
Pantethine (d-bis-(N-pantothenyl--aminoethyl)-disulfide,24
PAN) is the stable disulfide form of pantetheine, and the precursor25
of coenzyme A, an essential cofactor involved in ∼4% of primary26
metabolic pathways, playing a central role in the metabolism27
of fatty acids, polyketide and non-ribosomal synthases [1].28
Abbreviations: PAN, pantethine (d-bis-(N-pantothenyl--aminoethyl)-
disulfide); PD1, d-N-pantothenyl-N′--alanyl-bis(-aminoethyl)-disulfide;
PD2, bis-[N-(-alanyl)-2-aminoethyl]-disulfide, alethine; EHB, ethyl-p-
hydroxybenzoate; MHB, methyl-p-hydroxybenzoate; PHB, propyl-p-
hydroxybenzoate; HBA, p-hydroxybenzoic acid; CYS, cystamine dihydrochloride.
∗ Corresponding author. Tel.: +39 321375854/+39 321375821;
fax: +39 321375821.
E-mail addresses: giorgio.grosa@pharm.unipmn.it, grosa@pharm.unipmn.it
(G. Grosa).
Pantethine has beneficial effects in vascular diseases being able 29
to decrease the hyperlipidaemia, moderate the platelet function 30
and prevent the lipid-peroxidation [2]. Additionally its positive 31
role on cataract and cystinosis diseases was also proved [3,4]. 32
Moreover recent and exciting studies showed that administration 33
of pantethine prevented the cerebral syndrome in Plasmodium 34
berghei ANKA-infected mice preserving the blood-brain barrier 35
integrity [5]. These features suggested the possibility that, in 36
combination with anti-parasitic treatment, pantethine may be 37
an effective therapeutic agent for cerebral malaria [5,6]. Finally, 38
the role of pantethine in the treatment of neurodegenerative 39
processes (e.g. Parkinson’s disease) has been also reported [7]. 40
Overall, one of the most favourable aspects of pantethine is that 41
this molecule is a well-tolerated therapeutic agent being the 42
frequency of its side-effects very low and mild [8]. Pantethine 43
as active ingredient is currently available in two forms: a highly 44
compressible 55% powder (Pantesin® HF 55) and the 80% liquid 45
http://dx.doi.org/10.1016/j.jpba.2014.04.025
0731-7085/© 2014 Elsevier B.V. All rights reserved.
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form, the last one generally in combination with a preservative46
system. While Pantesin® may be advantageously employed in47
the formulation of tablets or capsules with minimal processing48
required, the high potency liquid form may be used in the manu-49
facture of soft-gelatin elastic capsules: this is an excellent choice50
for high-dosage forms and multiple ingredient formulations. It is51
worth of mention that PAN is considered at the same time, a drug52
and a dietary supplement depending on the country in which it is53
commercialized.54
Despite increasing number of studies dealing with the biolog-55
ical activities of PAN showing its potential role in the treatment56
of relevant vascular and neurodegenerative diseases, a compre-57
hensive search of the relevant literature did not yield any results58
on its chemical stability and its analytical aspects. Hence, no vali-59
dated stability-indicating LC method for the determination of PAN60
indrug substanceanddrugproducthasbeen so farpublished. These61
features suggested that an investigation on the stability of PAN62
and the development of a suitable stability-indicating analytical63
method are demanding in light of the requirements of the current64
international guidelines [9]. Hence, in the present work we have65
established for the first time the intrinsic chemical stability of PAN66
through a forced degradation study and LC–ESI–MS/MS investiga-67
tion. Based on these data a stability-indicating LC–UV method for68
simultaneous estimation of PAN, its main degradation product and69
preservative systemwas developed. The validation of the proposed70
method was also carried out and its applicability was evaluated71
analyzing the available commercial forms.72
2. Experimental73
2.1. Reagents and chemicals74
Pantethine (C22H42N4O8S2 Mw: 554.72, >99%), methanol75
(HPLC grade), potassium phosphate monobasic, sodium phosphate76
dibasic, concentrated ortophosphoric acid, iron(III) trichloride hex-77
ahydrate, copper sulphate pentahydrate, dichloromethane, 30%78
w/whydrogenperoxide solution, cystaminedihydrochloride (CYS),79
methyl-p-hydroxybenzoate (MHB), ethyl-p-hydroxybenzoate80
(EHB), propyl-p-hydroxybenzoate (PHB), p-hydroxybenzoic81
acid (HBA), sodium 1-pentanesulfonate, poly(ethylene glycol)82
400, glycerol, (hydroxypropyl)methyl cellulose, l-leucine -83
chloropropionyl chloride, sodium azide and triphenylphosphine84
were purchased from Sigma-Aldrich (Milano; Italy). Water (HPLC85
grade) was obtained from Milli-Q RO system. The drug product,86
Pantethine® soft-gelatin capsules, and the drug substance pan-87
tethine working standard (80%) were obtained as gift samples88
from Pharmafar S.r.l. (Torino, Italy). Pantethine working standard89
contained water (20%) and a preservative system constituted90
by a MHB and PHB mixture. The drug product Pantethine®91
soft-gelatin capsules contained PEG400 and glycerol as excip-92
ients. Moreover the preservative EHB is used in the capsule93
shell manufacturing process. The dietary supplement Pantethine94
capsules, containing the active ingredient Panthesin® and the95
excipients ((hydroxypropyl)methyl cellulose and l-leucine,96
(Allergy Research Group LLC, Alameda, CA, USA) was purchased97
on-line. The main physico-chemical properties of pantethine,98
parabens and their related substances were herewith reported:99
CYS (clogP: 0.62, pKa 8.60) [10,11]; PAN (logP: −4.17) [12];100
PD2 (bis-(N--alanyl--aminoethyl)-disulfide, alethine) (clogP101
−1.29±0.57, cpKa 9.24±0.10); HBA (logP: 1.58; pKa: 4.54); MHB102
(logP: 1.96; pKa: 8.4); EHB (logP: 2.47; pKa: 8.34); PHB (logP:103
3.04; pKa: 8.34) [13,14]. cLogP and cpKa values were calculated104
using Advanced Chemistry Development (ACD/Labs) Software105
V11.02.106
2.2. Instrumentation and chromatographic conditions 107
2.2.1. LC–UV analyses (method A) 108
A Shimadzu HPLC system (Shimadzu Europe GmbH, Duisburg, 109
Germany), consisting in twoLC-10ADVpmodulepumpsandaDGU- 110
14-Aon-line vacuumdegasser,was used. The analyseswere carried 111
out on a Luna C18(2) (150×4.6mm I.D., 5m dp; Phenomenex, 112
Torrance, CA, USA) column as a stationary phase. The composi- 113
tion of themobile phasewas: eluant A: sodium1-pentanesulfonate 114
(8mM) in aqueous phosphate buffer (pH=2.5; 20mM); eluant B: 115
sodium 1-pentanesulfonate (8mM) in phosphate buffer (pH=2.5; 116
20mM)–CH3OH (20:80 v/v). The following gradient, at a constant 117
flow rate of 1.5mLmin−1, was used: from 0 to 10min, the com- 118
position was increased from 37.5 to 100% B. From 10 to 12min 119
the percentage of eluant B was decreased to 37.5% and then main- 120
tained 6min for column equilibration (method A). The eluants A 121
and B were filtered through a 0.45m PVDF membrane filter prior 122
the use. A SIL-10AD Vp autosampler was used for the injection of 123
samples (20L). The SPD-M10A Vp photodiode array detector was 124
used to detect PAN and preservatives (MHB and PHB) at 254nm 125
and the degradation products (PD1) at 210nm. A LC solution 1.24 126
software (Shimadzu) was used to process the chromatograms. All 127
the analysis were carried out at room temperature. 128
2.2.2. Semipreparative LC–UV (method B) 129
Semipreparative chromatography was performed on a Waters 130
LC systemequippedwith amodel 2487 dual  absorbance detector, 131
a model 600 controller and a Delta 600 pump system (Waters Cor- 132
poration, Milford, MA, USA); the separations were carried out on 133
a Luna C18(2) (250×10mm I.D., 5m dp; (Phenomenex) column 134
as a stationary phase. The mobile phase consisted in a mixture of 135
eluant A: H2O/CH3OH 80/20 and eluant B: H2O/CH3OH 20/80 using 136
the following gradient at a constant flow rate of 4.5mLmin−1: from 137
0 to 9min the composition was maintained at 0% B then, from 9 to 138
9.5min, increased to 100% B. From 9.5 to 16min the percentage of 139
eluant B was maintained to 100%. Finally from 16 to 16.50min the 140
percentage of eluant Bwasdecreased to 0% and thenmaintained for 141
6min for column equilibration. A 7775 Rheodyne valve was used 142
for the injection of samples (100L, injected mass: ∼35mg). The 143
detectorwas set at254nm.TheEnpower1 software (WatersCorpo- 144
ration)was used to process the chromatograms. All the separations 145
were carried out at room temperature. 146
2.2.3. LC–MS/MS analyses (method C) 147
A Thermo Finningan LCQ Deca XP Plus system equipped with 148
a quaternary pump, a Surveyor AS autosampler, a Surveyor PDA 149
detector and a vacuum degasser was used for LC–MS analysis 150
(Thermo Electron Corporation, Waltham, MA, USA). 151
The analysis were performed on a Luna C18(2) (150×4.6mm 152
I.D., 5m dp; (Phenomenex) column as a stationary phase main- 153
tained at 35 ◦C. The mobile phase (flow rate 0.8mLmin−1) was 154
composed of eluant A: H2O (0.1% v/v HCOOH) and eluant B: CH3OH 155
using a linear gradient: from 30% to 80% solvent B in 10min, 156
afterward the B fraction was decreased to 30% in 2min and then 157
maintained for6min for theequilibration; the sample injectionvol- 158
ume was 10L. The eluate was injected into the electrospray ion 159
source (ESI) with a splitting of 40% and the MS and MS/MS spectra 160
wereacquiredandprocessedusing theXcalibur® software (Thermo 161
ElectronCorporation). Theoperatingconditionsof the ion trapmass 162
spectrometer in positive ion mode were the following: spray volt- 163
age, 5.30kV; source current, 80A; capillary temperature, 350 ◦C; 164
capillary voltage, 44.0V; tube lens offset, −20V; multipole 1 offset, 165
−8V; multipole 2 offset, −21.50V; sheath gas flow (N2), 55 Aux- 166
iliary Units; sweep gas flow (N2): 8.0 Auxiliary Units. Data were 167
acquired both full scan and MS/MS product ion scan modes using 168
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mass scan range m/z 110 to 500, optimizing the collision energy at169
32–35%.170
2.2.4. 1H,13C-NMR and spectroscopic analyses171
1H and 13C experiments were performed on a JEOL Eclipse172
ECP 300 FT MHz spectrometer (Jeol Ltd. Tokyo, Japan) operating173
at 7.05T. Chemical shifts are reported in part per million (ppm).174
UV–vis and FT-IR experiments were performed on a Lambda 35175
(Perkin-Elmer, Waltham, MA, USA) and on AVATAR 370 FT-IR176
(Thermo Fisher Scientific, Madison, WI, USA) spectrophotometers,177
respectively.178
2.3. Chemical stability179
2.3.1. Forced degradation study180
All degradation studies in solution were done at a PAN (80%181
working standard) concentration of 1mgmL−1. For acidic degrada-182
tion study, PAN was dissolved in 0.1M HCl and the solution was183
left in the dark at ambient temperature for 24h or alternatively184
for 6h at 45 ◦C. The degradation in alkaline conditions was done185
in 0.01M NaOH and the solution was left in the dark at ambient186
temperature for 5h. To test the stability in neutral solution, PAN187
was dissolved in water and left at room temperature or at 60 ◦C188
for 18h. For oxidative conditions, the degradation was done in a189
1% hydrogen peroxide solution and it was left in the dark at room190
temperature for 5h. Moreover, to evaluate the influence of transi-191
tion metals, PAN solution was treated with 1.5mM Cu2+ or Fe3+ at192
ambient temperature for 3h. For thermal stress, PAN was placed in193
a hot air oven maintained at 60 ◦C for 18h. Photodegradation stud-194
ies were carried out, at room temperature, by exposing a thin layer195
(50mg) of PAN to daylight and UV–light (366nm) for 240 and 6h,196
respectively.197
Before LC–UV (method A) and LC–MS/MS (method C) analyses,198
acidic and alkaline samples were first neutralized by addition of199
a suitable amount of sodium phosphate dibasic and concentrated200
phosphoric acid, respectively, and then diluted by adding an appro-201
priate volume of mobile phase. The samples arising from oxidative,202
thermal and photolytic stresses, were diluted with an appropri-203
ate volume of mobile phase. For comparison purposes a freshly204
prepared aqueous solution of PAN (1mgmL−1) was diluted and205
analyzed as above.206
2.3.2. Long-term and accelerated stability studies207
The stability study was performed in a Binder-KBF-115 con-208
stant climate chamber (Binder GmbH, Tuttlingen Germany). Drug209
product (Pantethine® soft-gel capsules) packaged in the container210
closure system used for marketing was stored using the following211
conditions: long-term study: 25 ◦C±2 ◦C 60% RH±5%, 24 months.212
2.4. Preparation of reference samples of the degradation products213
The reference sample of PD1 was obtained from thermal214
stress of pantethine and isolated and purified by semipreparative215
LC–UV (method-B) (Supplemental 1). The reference sample of PD2216
(bis-[N-(-alanyl)-2-aminoethyl]-disulfide)was obtained from the217
synthetic procedure reported in Supplemental 2. The structural218
characterization of PD1 and PD2was also reported in Supplemental219
1 and 2).220
2.5. Preparation of standard and sample solutions221
2.5.1. Preparation of standard stock solutions for validation222
process223
The standard solutionsof PAN (8mgmL−1), PD1(1mgmL−1) and224
CYS (1mgmL−1) were prepared using water as solvent. The com-225
bined standard solution of preservatives MHB (40gmL−1) and226
PHB (40gmL−1) was prepared in a CH3OH/H2O 20:80 (v/v) mix- 227
ture. The standard solution of HBA (4.75gmL−1) was prepared by 228
dissolving an appropriate amount (about 47.5mg) ofHBA in100mL 229
95/5 H2O/CH3OH mixture; 2.0mL of the solution were diluted to 230
200mL using water as solvent. The stock solutions were properly 231
diluted with water to obtain the working solutions that have been 232
used in the validation protocol. 233
2.5.2. Preparation of test solutions 234
2.5.2.1. Test solution for PAN assay. The contents of 20 capsules of 235
the drug product Pantethine® or of the dietary supplement Pan- 236
tethine were accurately mixed and about 550mg of the mixture 237
were weighted and transferred into a 250mL volumetric flask. The 238
volumetric flask was filled to volume with water. After filtration 239
through 0.45m PVDF membrane filter, the sample was analyzed 240
by LC–UV (method A). 241
2.5.2.2. Test solution for degradation product assay. The solution 242
waspreparedwith the sameprotocoldescribedaboveusinga50mL 243
volumetric flask. 244
2.6. Validation procedure of method-A 245
2.6.1. System suitability 246
The system suitability parameters, resolution (Rs), area repeata- 247
bility and asymmetry factor (As) were calculated as previously 248
reported [15]. 249
2.6.2. Selectivity 250
To assess the method selectivity a combined reconstructed cap- 251
sule formulation without PAN was prepared using the excipients 252
used for the drug product Pantethine® (PEG400 and glycerol) and 253
for dietary supplement Pantethine ((hydroxypropyl)methyl cellu- 254
lose and l-leucine). For HPLC analysis the solution was prepared 255
using the same procedure of analytical sample. Moreover to evalu- 256
ate the chromatographic separation of the analytes PAN, PD1, MHB 257
and PHB from the impurities arising from capsule shell (EHB) or 258
from synthetic (CYS) and degradation (PD2 and HBA) processes, 259
a combined standard solution was prepared and analysed. After 260
LC–UV analyses, resolution factors were calculated. 261
2.6.3. Robustness 262
To determine the robustness three parameters were varied: 263
mobile phase pH, counter-ion concentration and the percentage 264
composition of eluant. The influence of the pH of the mobile phase 265
was studied by analyzing the standard mixture of analytes CYS, 266
HBA, PAN,MHB, PHB, EHB and PD1 at three different values: 2.4, 2.5 267
and 2.6 being 2.5 the reference value. The influence ofmobile phase 268
composition was determined by varying the initial (28–30–32%) 269
andfinal (76–80–84%) percentages of eluant B. Finally the influence 270
of the variation of the counter-ion (sodium 1-pentanesulfonate) 271
concentration was studied in the range 7.5–8.5mM being 8.0 the 272
reference value. In all cases the effects of the small changes brought 273
to the method have been evaluated by calculating the resolution 274
factors. 275
2.6.4. Stability of standard and test solutions 276
To study the stability of the standard and test solutions, analy- 277
ses at t=0 and after 12h at room temperature storage were done. 278
Results were expressed as percent of PAN remaining. 279
2.6.5. Linearity 280
Linearity of the method was evaluated at five equispaced 281
concentration levels by diluting the standard solutions to give 282
solutions over the range 50–150% of the target concentration for 283
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PAN and parabens (MHB and PHB) and 0.05–2.0% for degrada-284
tion product PD1. These were injected in triplicate and the peak285
areas were inputted into a Microsoft Excel® spreadsheet program286
to plot calibration curves. To fulfil basic requirements such as287
homoscedasticity and linearity, the Bartlett test and the lack-of-fit288
test were, respectively, performed at the 95% significance level.289
2.6.6. Precision290
Precision was evaluated in terms of repeatability and interme-291
diate precision.292
The repeatability was investigated using six separate sample293
solutions prepared, as reported above, from the freshly recon-294
structed capsule formulation at 100% of the target level. Each295
solutionwas injected induplicate and thepeak areas obtainedwere296
used to calculate means and RSD values.297
The intermediate precision was checked on four different days,298
by preparing and analysing in triplicate four separate sample299
solutions from the reconstructed formulations at the same con-300
centration level of repeatability; the means and RSD values were301
calculated from peak areas.302
2.6.7. Accuracy303
To assess accuracy, freshly prepared combined placebo of the304
pharmaceutical formulations was spiked with various amounts of305
PAN, MHB and PHB at 50, 100 and 150% concentration levels and306
PD1 at 0.05, 0.1 and 1.0% concentration levels. Each solution was307
injected in triplicate and the peak areas were used to calculate308
means and RSD values and compared with those obtained with309
standard solutions.310
2.6.8. LOD–LOQ311
Thedetermination of LODand LOQwas based on signal-to-noise312
ratio: thiswas evaluatedby comparingmeasured signals fromsam-313
ples with known low concentrations of PD1 with those of blank314
samples and by establishing the minimum concentration at which315
the analyte can be reliably detected (LOD; signal-to-noise ratio =3)316
or quantified (LOQ; signal-to-noise ratio =10).317
2.6.9. Determination of PD1 relative response factor (RRF)318
PD1 and PAN solutions at 50gmL−1 concentration were pre-319
pared by dilution of the corresponding standard solutions; the320
replicated LC–UV (method A) analyses (n=6) were performed at321
a =210nm and peak areas of PD1 and PAN were integrated. RRF of322
PD1wascalculatedusing the following formulaRRF=PD1area/PAN323
area.324
3. Results and discussion325
3.1. Forced degradation study and structural characterization of326
degradation products327
The degradation of PAN in neutral, alkaline and acidic solu-328
tions and in the presence of other stress conditions (e.g. oxidative,329
thermal and photolytic) has never been previously reported in the330
literature. In the present forced degradation study all the stress331
conditions required by ICH guidelines were included; moreover,332
in order to avoid unrealistic degradation pathways, the conditions333
were fixed to obtain about 10–20% degradation of the parent com-334
pound. As a matter of fact, in 0.01M NaOH and 0.1M HCl the335
degradation of PAN took place with the formation of the common336
andmorepolar degradationproduct PD1 (tR=4.45min) as reported337
in LC–UV chromatograms (Fig. 1a1 and b1). It is worth of mention338
that peaks appearing at tR=7.4 and 10.8min corresponded to MHB339
andPHBpreservatives. Increasing the reaction timeor temperature,340
the formation of another degradation product, PD2 (tR=3.15min)341
was observed; similarly, the increase of HBA peak (tR=3.95min),342
mainly in the alkaline solution, was also observed (Fig. 1a2). The 343
presence of several amide functions in the structure of PAN sug- 344
gested that their hydrolysis could cause the formation of different 345
degradation products whose structures were investigated analyz- 346
ing the reaction mixtures by liquid chromatography tandem mass 347
spectrometry. The extracted ion chromatograms (Supplemental 348
3) obtained from positive full scan analysis of the alkaline sam- 349
ples revealed the presence of three peaks corresponding to PAN 350
(m/z=555, tR=6.94min), PD1 (m/z=425, tR=2.79min), and PD2 351
(m/z=295, tR=2.25min) whose MS spectra are reported in Supple- 352
mental 4. Thedegradationproducts PD1andPD2were identifiedby 353
monitoring thepositive ions related to theproductsarising fromthe 354
hydrolysis of one or two amide functions, respectively. The positive 355
product ion spectrum of PD1 (m/z=425) depicted in Fig. 2a shows 356
several diagnostic fragment ions at m/z 407 (loss of water), 295 357
(amide cleavage) and subsequent loss of ammonia (278). On the 358
contrary PD2 (m/z=295) protonated molecule (Fig. 2b) only shows 359
the fragment ion atm/z278 (loss of ammonia). The peaks appearing 360
at tR=6.94min (Supplemental 3, trace B) and 2.88min (Supple- 361
mental 3, trace C) were attributed to artifacts arising from the 362
in-source fragmentation of PAN (peak with tR=6.94min) and PD1 363
(peak with tR=2.88min); indeed already during in source charged 364
droplet desolvation and before collision-induced dissociation, PAN 365
underwent both single or double amide cleavage, being present the 366
ions atm/z 425 and 295 in its full scan spectrum. The sameoccurred 367
for PD1 which can only generate the ion at m/z 295 (see mass spec- 368
trum in Supplemental 4). The structure of PD1 was confirmed by 369
the isolation and purification of a reference sample from PAN ther- 370
mal degradation (Supplemental 1) using semipreparative LC–UV 371
(method B). The purity of PD1 reference sample was 97.8% and its 372
1H-NMR spectrum showed the presence of the singlet signals at 373
0.9 and 3.9ppm referable to the equivalent methyl protons (C3 and 374
C4) and the C5 proton, respectively, belonging to the pantoic acid 375
residue: in particular the analysis of their intensities, done by inte- 376
gration, indicated the presence of only one residue of pantoic acid. 377
These data were confirmed by 13C-NMR spectrum where the sig- 378
nals of only three carbonyl groups were present at 175.5, 173.4 and 379
171.9ppm. 380
The structure of PD2 was attributed by comparison of its reten- 381
tion time and MS/MS data with those of the synthetic standard 382
obtained in a three-step synthesis starting from cystamine (Sup- 383
plemental 2). The structure of PD2 reference sample was assigned 384
by 1H- and 13C-NMR analyses. In the 1H-NMR spectrum the lack 385
of diagnostic signals (0.9 and 3.9ppm) arising from pantoic acid 386
residue was observed, while the triplets from methylenic protons 387
were present at 3.5, 2.9, 2.8 and 2.4ppm. Finally, as expected, a sin- 388
gle signal referable to the symmetrical carbonyl groups (C3 and C8) 389
was present in the 13C-NMR spectrum confirming the structure of 390
alethine for PD2. LC–MS and MS/MS analysis of PAN in acidic solu- 391
tions showed the formation, even if to a minor extent, of the same 392
degradation products already described for alkaline degradation. 393
In neutral aqueous solution at ambient temperature, PAN was sta- 394
ble, however at 60 ◦C a degradation productwas observed in LC–UV 395
chromatogram (Supplemental 5) being its retention time and mass 396
spectral data identical to those of PD1. 397
Regarding HBA peak, its presence and its increase in alkaline 398
stressed samples did not appear in relation with PAN degradation. 399
Indeed, even if HBAwas also present, as a low-intensity peak, in the 400
chromatograms obtained from other stress conditions, it was not 401
in that of a freshly prepared solution of pantethine working stan- 402
dard (Supplemental 11). Moreover HBA was not observed in the 403
chromatograms obtained from Pantethine hard capsules (Supple- 404
mental 13) a paraben-free preparation. Hence, taking into account 405
the preferential formation of HBA in alkaline conditions and the 406
presence of methyl and propylparaben esters in the pantethine 407
working standardand its correspondingdrugproduct, the structure 408
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Fig. 1. LC–UV (method A; a =254nm) chromatograms of PAN in 0.01M NaOH solution at room temperature ((a1) t=5h; (a2) t=8h) and in 0.1M HCl solution ((b1) t=25 ◦C,
t=24h; (b2) t=45 ◦C, t=6h).
of p-hydroxybenzoic acid for HBA was proposed. The assignment409
was confirmedby comparing its chromatographic propertieswith a410
reference standard of HBA. The oxidative degradation pathwaywas411
studied using two different protocols. In the presence of hydrogen412
peroxide, as reported in LC–UV chromatogram (Fig. 3), a degra-413
dation product was formed (POx). As expected, LC–ESI–MS/MS414
analysis provided a protonated molecule at m/z 571, +16Da with415
respect to PAN.416
The protonated molecule at m/z 571 and its fragment ion at417
m/z 441 (amide cleavage; Fig. 4) indicated the insertion of an oxy-418
gen atom in the structure of PAN suggesting the formation of the419
thiosulfinate derivative. POx appeared quite unstable and this fea-420
ture prevented its purification and the complete physico-chemical421
characterization.422
Even if hydrogen peroxide was the most used stress condition,423
the role of transition metals in oxidative stress could be also eval-424
uated, being different their mechanism of reaction [16]; however425
PAN was found to be stable in other oxidative stress conditions:426
indeed in Fe3+ and Cu2+ aqueous solutions PAN did not undergo427
degradation (data not shown). The photodegradation was studied428
exposing PAN to day light and 366nm UV–light without observing429
the formation of degradation products (data not shown). On the430
contrary thermal stress condition caused the formation of PD1 as431
the only degradation product as reported in Supplemental 6.432
Dataobtained fromthe forceddegradation studyallowed topro-433
pose the degradation scheme of pantethine reported in Fig. 5. The434
main degradation pathway is represented by thermal/hydrolytic435
cleavage of amide functions. In particular, the first degradation436
step involved one of the terminal amide group with the formation437
of PD1 and, possibly, pantolactone as the leaving group. The easy438
dissociation of the terminal amide function could be attributed to 439
the neighbouring group effect of the end-position hydroxyl group. 440
If the reaction time and/or severity of the stress conditions were 441
increased the formation of the symmetrical degradation product, 442
PD2, was observed through the hydrolysis of the other terminal 443
amide function. Finally, another degradation pathway of PAN was 444
represented by the oxidation, possibly involving the formation of 445
pantethine thiosulfinate POx. From a pharmaceutical point of view, 446
the relevance of the degradation products of PANwasnot the same; 447
indeed PD2, a secondary degradation product, and POx were never 448
observed in long-term stability studies of PAN and its formulation; 449
on the contrary, PD1 can be effectively considered the indicator of 450
stability for hydrolytic and thermal stresses and it was included in 451
the development and validation of the analytical assay. 452
3.2. LC–UV method development 453
Dataobtained fromforceddegradation studyallowed todevelop 454
a LC–UV assay for determination of PAN, its degradation product 455
PD1 and the preservative system constituted by MHB and PHB. 456
Moreover, to properly assess the selectivity of the method the 457
potential impurity CYS was also included in method development: 458
indeed one of the approaches for the synthesis of PAN is based 459
on the condensation of CYS with pantothenic acid. Similarly, the 460
other degradation product of PAN, PD2 and the degradation prod- 461
uct of preservant system HBA were also included in selectivity 462
assessment. Overall, the analytes showed very different struc- 463
tural features as well as physico-chemical properties; hence their 464
chromatographic separation was a challenging task. Indeed, while 465
free primary amino groups were present in PD1, PD2 and CYS, a 466
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Fig. 2. ESI–MS/MS spectra of PD1 (a) and PD2 (b).
Fig. 3. LC–UV chromatogram of PAN in 1% H2O2 solution (t=5h).
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Fig. 4. ESI-MS of Pox: full scan spectrum of the POx (a), and its MS/MS spectrum (m/z 571) (b).
Fig. 5. Degradation pathways of PAN.
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Fig. 6. LC–UV chromatogram (method A, a =254nm) of a solution containing CYS, PD2, HBA, PD1, PAN, MHB, EHB and PHB.
carboxylic group was present in HBA structure; moreover, there467
is a great difference in the lipophilicity of the parabens and the468
pantethine-related compounds: indeed their logP values vary in469
the wide range −4.17–3.04. During the method development, to470
select the appropriate chromatographic conditions for separating471
all the analytes, a number of stationary phases with various iso-472
cratic mobile phases, containing acetonitrile or methanol-aqueous473
phosphate buffers, were evaluated; however all the attempts to474
achieve the separation of all analytes have failed; in particular,475
a poor retention of the polar and the charged analytes (e.g. CYS,476
PD2 and PD1) was observed (data not shown). Taken together477
these results suggested the inclusion of an appropriate counter-478
ion and the use of a gradient elution to provide an increase of the479
lipophilicity of PD2, PD1 and CYS and a baseline resolution of all480
the analytes in an acceptable analysis runtime. Hence a pH=2.5481
phosphate buffer was chosen to promote the protonation of the482
amino groups of CYS, PD1 and PD2 and to suppress the ioniza-483
tion of HBA carboxylic group while reducing the ionization of484
stationary phase silanol functions: these features could mitigate485
their interactions with the analytes. Alkyl sulfonate sodium salts486
were used to form the ion-pairs with CYS, PD1 and PD2 being the487
counter-ion chain length and the concentration the critical factors488
to ensure the separation of the mixture of the analytes. In par-489
ticular, sodium pentanesulfonate at 8mM concentration provided490
the required method selectivity and robustness. Accordingly, the491
starting mobile phase was constituted by eluant A: aqueous phos-492
phate buffer (20mM pH=2.5, 8mM sodium 1-pentansulfonate)493
and eluant B: phosphate buffer (20mM, pH=2.5) 8mM sodium494
1-pentanesulfonate) theA:B ratio being62.5:37.5; the gradient elu-495
tionwasperformedat aflowrateof1.5mLmin−1. Theanalysiswere496
performed at 254nm for PAN, MHB and PHB assays; however, for497
the determination of degradation product (PD1) at 0.1% level of498
concentration, a =210nm was used. Overall, the selected analyti-499
cal conditions provided chromatograms at a =254nm (Fig. 6) and500
at a =210nm (Supplemental 7) with good peak shapes, required 501
for the simultaneous separation of a CYS, PD2, HBA, PD1, PAN,MHB, 502
EHB and PHB mixture with an acceptable time of analysis. It is 503
worth of mention that EHB was included in the method develop- 504
ment because of its presence in drug product during stability study: 505
indeed EHB migrates from the capsule shell to the content. 506
3.3. Method validation 507
The developed method was validated [17], as described below, 508
for the followingparameters: systemsuitability, specificity, robust- 509
ness, linearity, precision, accuracy and LOD/LOQ. 510
3.3.1. Selectivity 511
Selectivity is the ability of an analytical method to assess 512
unequivocally the analytes in the presence of components that 513
are present in the sample matrix. The chromatogram (Supple- 514
mental 8) of the placebo solution constituted by excipient blend 515
(poly(ethylene glycol) 400, glycerol, (hydroxypropyl)methyl cel- 516
lulose and l-leucine) showed no peak interfering with analytes; 517
moreover the adjacent chromatographic peaks (Fig. 6) CYS/PD2, 518
PD2/HBA, HBA/PD1, PD1/PAN, PAN/MHB, MHB/EHB and EHB/PHB 519
were separatedwith resolution values greater than 3 as reported in 520
Table 1. Certainly some excess of resolution could be found, in par- 521
ticular betweenPANandparabens andbetweenparabens, however 522
the increaseof the lipophylicity of PANand its related substancesby 523
using hexane/heptane/octanesulfonate sodium salts did not allow 524
the separation of the analytes. Overall, these data demonstrated 525
that the excipients and the degradation products did not interfere 526
with PAN peak, indicating the selectivity of the method. 527
3.3.2. System suitability 528
As system suitability tests are an integral part of chromato- 529
graphic method development and they are used to verify that the 530
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Table 1
System suitability parameters.
Repeatability of peak areaa Asymetry
factor
Resolution
PAN 0.4 0.9 CYS/PD2 5.8
PD1 0.9 1.0 PD2/HBA 3.9
MHB 0.2 1.1 HBA/PD1 3.9
PHB 0.4 1.0 PD1/PAN 7.8
PAN/MHB 8.5
MHB/EHB 11.4
EHB/PHB 11.5
a The concentrations of analytes were: PAN (0.8mgmL−1), PD1 (5.0gmL−1),
MHB and PHB (0.8gmL−1 each). a =254nm for PAN, MHB and PHB and
a =210nm for PD1.
The figures in parenthesis represent RSD values for six replicates.
system is adequate for theanalysis tobeperformed, resolution, area531
repeatability and asymmetry factorwere the parameters evaluated532
for the analytes PAN,MHB, PHB andPD1. The suitability of the chro-533
matographic systemwas demonstrated by comparing the obtained534
parameter values, reported in Table 1, with the acceptance criteria535
of the CDER guidance document [18].536
3.3.3. Robustness537
Even if the high resolution values between the peaks of analytes538
could confer the required robustness to the method, the role of the539
most critical method parameters (pH, counter-ion concentration540
and mobile phase composition) has been evaluated by introducing541
small but deliberate variations. As reported (Supplemental 9A), the542
resolution values were always greater than 2.7 also in the case of543
some potential critical pair of adjacent peaks (e.g. HBA/PD1).544
Moreover the standard and test solutions appeared stable over545
a 12h time period.546
3.3.4. Linearity547
Five concentration levels within 50–150% of the target concen-548
tration range for PAN, MHB and PHB were considered to study the549
linearity. For PD1 and PAN at 0.1% level of concentration, a range550
value of 0.05–2.0% was used. Since the Bartlett test evidenced no551
significant difference (p>0.05) among the variance values of repli-552
cates at different concentration levels the best fit was obtained553
using an unweighted linear regression model. The linearity was554
observed in the expected concentration ranges, demonstrating555
their suitability for analysis. The results of the regression statis-556
tics for all the analytes were reported in Table 2. The square of557
the correlation coefficient (r2 >0.999) demonstrated a significant558
correlation between the concentration of analytes and detector559
response; however it was neither a proof of linearity, nor a use-560
ful measure of the calibration variability. Hence the lack-of-fit-test561
were performed on these data; the significance values (p>0.05)562
obtained for all analytes indicated that a linear regression model563
provides a good interpolation of the experimental data. More- 564
over, the evaluation of residual plot confirmed that underlying 565
assumption like homoscedasticity was met as well as the goodness 566
of fit of the regression model. Finally the confidence interval of the 567
y-intercepts includes zero;moreover the relative residual standard 568
deviations, expressed as percentage, were calculated and used to 569
assess theprecisionof the regression: all valueswere <1%except for 570
those corresponding to PD1 and PAN at 0.1% level of concentration 571
(1.9 and 0.9%, respectively). 572
3.3.5. Precision 573
The precision of an analytical procedure expresses the degree of 574
scatter between a series of measurements obtained from multiple 575
sampling of the same homogeneous sample under the prescribed 576
conditions. The repeatability (intraday precision) refers to the use 577
of analytical procedure within a laboratory over a short period of 578
timeusing the sameoperatorwith the sameequipment. Intermedi- 579
ate precision (interday precision) involves estimation of variations 580
in analysis when a method is used within a laboratory on differ- 581
ent days, by different analysts. The results obtained are shown in 582
Supplemental 9B. In all instances RSD values were less than 2%. 583
3.3.6. Accuracy 584
Accuracy has been determined by application of the analytical 585
procedure to recovery studies, where known amount of standard 586
was spiked into the placebo. The results of accuracy studies were 587
shown in Supplemental 9C. The method demonstrated to be accu- 588
rate as the average recoverieswere 100.2, 99.9, and 100.0% for PAN, 589
MHB and PHB, respectively, and 99.9 for PD1. Moreover PAN at 590
0.1% level of concentration showed an acceptable average recovery 591
(100.5%). 592
3.3.7. LOD–LOQ 593
LOD and LOQ were determined at 210nm, by injecting progres- 594
sively low concentration solutions of PD1 and PAN. PAN and PD1 595
showed the same values of LOD and LOQbeing 0.8 and 2.5gmL−1, 596
respectively. 597
3.3.8. PD1 relative response factor (RRF) 598
RRF of PD1 was obtained by comparing the peak areas (Supple- 599
mental 10) of PD1 and PAN at the same concentration (50gmL−1; 600
a =210nm); as expected, due to the similarity of their chemical 601
structures RRF value was 1.0. 602
3.4. Analysis of PAN capsule formulations 603
LC–UV chromatogram, obtained fromPantethine® capsule sam- 604
ple employed in a long term stability study (t=24 months; 605
Supplemental 12A) allowed to detect the formation of PD1 as the 606
degradation product of PAN and HBA as the degradation product of 607
the preservatives; on the contrary the presence of PD2 was never 608
Table 2
Five levels calibration graphs for PAN, MHB, PHB and PD1: unweighted regressions y= ax+b; three replicates for each level (n=15).
PAN MHB PHB PD1 PANa
Range 0.4–1.2mgmL−1 0.4–1.2gmL−1 0.4–1.2gmL−1 2.5–100gmL−1 2.5–100gmL−1
Slope (a) 482,484 79,677 68,108 10,377.3 10,882.3
Standard error (SE) (a) 1750.3 368.9 300.1 34.9 26.0
Intercept (b) −2402.8 3.74 138.6 −2832.4 1349.9
(b) C.I.b −5611.3–805.7 −672.6–680.1 −411.6–688.7 −6701.5–1036.7 −1533.6–4233.4
F 75,988.4 p<0.01 46,639.0 p<0.01 51,500.1 p<0.01 88,342.3 p<0.01 174,916.0 p<0.01
r2 0.9998 0.9997 0.9997 0.9998 0.9997
RRSDc 0.5 0.6 0.6 1.9 0.9
a Pantethine at 0.1% level of concentration.Q5
b 95% confidence interval.
c Relative residual standard deviation.
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found during the study. It is worth noting that PD1 increases over609
the time, during the stability study showing its hydrolytic instabil-610
ity. Moreover the presence of EHB arising from the capsule shell,611
was also shown. Finally the presence of two unknown impurities612
(U1 and U2 at ∼5.5 and 6.8min, respectively) was observed in613
the LC–UV chromatogram (Supplemental 12B). In the case of Pan-614
tethine hard gelatine capsule formulation (Supplemental 13A), the615
expected lack of peaks of parabens was confirmed along the pres-616
ence of PD1 peak. Furthermore the presence of a third unknown617
impurity (U3, at ∼6.4min; Supplemental 13B) was also found. It618
is worth of mention that the unknown impurities (U1–U3) were619
not observed during the forced degradation study and the peak620
intensities of U1 and U2 did not change over the time period of the621
stability study: taking together these features suggest that U1–U3622
could arise from synthetic procedures of PAN.623
4. Conclusions624
In the present work the intrinsic chemical stability of PAN was625
for the first time investigated by LC–MS/MS technique and a degra-626
dation scheme was proposed on the basis of a forced degradation627
study. The identification and synthesis of the main degradation628
products allowed the development and validation of a comprehen-629
sive stability-indicating LC–UV method for the determination of630
PAN, its degradation product PD1 and the preservative system in631
the drug substance and drug product. The complete separation of632
eight analytes was accomplished in 12min and the method has633
been successfully used to perform stability studies of PAN formu-634
lations.635
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